The initial goal was 3D printing tissue. However, the hydrogel's excellent processability (mixability, pumpability) was also the solution to a major bottleneck in drug discovery: automating 3D cell cultures in high-throughput screening (HTS) systems. This secondary characteristic unlocked a better, more immediate market.

Traditional 2D cell cultures can be misleading. Advanced 3D models, by reconstituting the tumor microenvironment with stromal cells, can uncover mechanisms of drug resistance (e.g., to ADCs) that are completely invisible in simpler systems, providing more clinically relevant data.

The move to animal-free components in cell culture presents a major scientific hurdle, as cells did not evolve to grow in them. However, the key benefit is strategic. Synthetically-defined materials eliminate the batch-to-batch variability of animal-derived matrices, enabling the reproducibility and process control essential for industrial-scale manufacturing.

Only 5% of investigational cancer drugs reach the market due to the gap between lab models and human biology. Dr. Saav Solanki highlights organoids, which use real patient tissue, as a key translational model to improve the predictive accuracy of preclinical research and increase the low success rate.

The primary obstacle to creating sophisticated AI models of cells isn't the AI itself, but the data. Existing datasets often perturb only one cellular variable at a time, failing to capture the complex interactions that arise from simultaneous changes. New platforms are needed to generate this multi-dimensional data.

Unlike inert materials, living tissues adapt. A metal splint that is too strong will cause the adjacent bone to atrophy because the splint carries the load, signaling the bone is no longer needed. This highlights a key challenge in biomedical engineering: designing for dynamic biological systems.

The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.

A 3D model is considered "advanced" when it's a bioactive system recreating a tissue's microenvironment. It's not just about three-dimensional growth; cells must both influence and be influenced by their surroundings, including architecture, diffusion gradients, and mechanical cues, to be truly representative.

The paradigm for stem cells is shifting. Instead of using them for their innate therapeutic properties, the "MSC 2.0" vision treats them as a chassis. Once engineering and manufacturing are solved, you can encode diverse biological functions into them, turning them into programmable vehicles for various payloads and diseases.